康泰医学(300869) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥122,747,980.40, a decrease of 5.62% compared to the same period last year, while year-to-date revenue increased by 33.55% to ¥617,227,119.11[5] - Net profit attributable to shareholders for Q3 2023 was ¥12,231,121.05, down 79.21% year-on-year, with year-to-date net profit increasing by 12.00% to ¥195,117,554.43[5] - Total operating revenue for Q3 2023 reached ¥617,227,119.11, an increase of 33.6% compared to ¥462,183,267.50 in Q3 2022[22] - Net profit for Q3 2023 was ¥195,117,554.43, representing a 12% increase from ¥174,206,387.64 in Q3 2022[23] - Earnings per share for Q3 2023 were ¥0.4856, compared to ¥0.4336 in Q3 2022, reflecting a growth of 11.5%[23] Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was ¥177,722,313.98, representing a significant increase of 164.98% compared to the same period last year[9] - The cash inflow from operating activities for the current period was CNY 838,260,774.94, an increase of 46.5% compared to CNY 572,358,761.95 in the previous period[24] - The net cash flow from operating activities was CNY 177,722,313.98, significantly up from CNY 67,069,817.19 in the same period last year[24] - The cash outflow from investing activities totaled CNY 838,773,729.34, compared to CNY 60,205,874.69 in the previous period, resulting in a net cash flow from investing activities of -CNY 717,018,969.77[24] - The cash inflow from financing activities was CNY 752,371,600.44, down from CNY 1,677,460,871.21 in the previous period, leading to a net cash flow from financing activities of -CNY 491,943,768.13[25] Assets and Liabilities - The company's total assets as of September 30, 2023, were ¥3,466,231,813.74, a decrease of 7.14% from the end of the previous year[5] - Total liabilities for Q3 2023 were ¥1,391,513,671.50, down from ¥1,804,472,003.19 in Q3 2022[20] - The company's cash and cash equivalents decreased to ¥464,284,446.43 from ¥820,878,367.09 year-over-year[20] - The total non-current assets include fixed assets valued at ¥270,211,824.39, slightly up from ¥267,898,744.46 at the beginning of the year[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 41,237[11] - The largest shareholder, Hu Kun, holds 46.84% of shares, totaling 188,189,252 shares[11] - The total number of shares held by the top ten unrestricted shareholders is 53,000,000[11] - The total number of restricted shares held by Hu Kun is 141,141,939, with 47,047,313 shares released during the period[15] - The company has a total of 249,569,772 restricted shares, with 47,047,313 shares released during the reporting period[15] Operating Costs and Expenses - The gross profit margin for the first nine months of 2023 was impacted by a 55.53% increase in total operating costs, which reached ¥429,154,337.97[8] - Total operating costs for Q3 2023 were ¥429,154,337.97, up 55.4% from ¥275,929,037.90 in the same period last year[22] - Research and development expenses for Q3 2023 were ¥79,806,439.64, an increase of 20.5% compared to ¥66,072,763.60 in Q3 2022[22] Investment and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 1,293.88% to ¥650,058,191.78, attributed to increased investment in financial products[8] - The company reported an investment income of ¥57,106,608.77 in Q3 2023, compared to no investment income in the same period last year[22] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 0.59%, down 2.60% year-on-year, while year-to-date it was 9.71%, an increase of 0.31%[5] - The company's cash and cash equivalents decreased by 73.94% to ¥362,964,487.15 due to cash management strategies[8] - Deferred tax assets decreased to ¥1,360,792.34 from ¥1,808,915.66 year-over-year[20] - The company received CNY 632,878,400.00 in borrowings, a decrease from CNY 794,877,357.32 in the previous period[25] - The company paid CNY 976,810,125.90 in debt repayments, an increase from CNY 708,579,290.00 in the previous period[25] Audit Status - The third quarter report was not audited[26]